NEW YORK, Aug. 11, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Gemini Therapeutics, Inc. ("Gemini" or the "Company") (NASDAQ: GMTX), in connection with the proposed merger of the Company with Disc Medicine, Inc. ("Disc").  Under the terms of the merger agreement, Gemini shareholders are expected to own approximately 28% of the combined company and Disc shareholders are expected to own approximately 72% of the combined company.  Prior to the closing of the proposed merger, Company shareholders will be issued contingent value rights ("CVR's) representing the right to receive certain payments from proceeds received by the combined company, if any, related to pre-transaction legacy assets during the period ending one year following the closing of the merger. 

If you own Gemini shares and wish to discuss this investigation or have any questions
concerning this notice or your rights or interests, visit our website:

https://www.weisslaw.co/news-and-cases/gmtx 
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7^th Floor
New York, NY  10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Weiss Law is investigating whether (i) Gemini's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Gemini's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-weiss-law-investigates-gemini-therapeutics-inc-301604476.html

SOURCE Weiss Law